{"id":"methylene-blue","rwe":[],"_fda":{"id":"47e8083a-60e6-b517-e063-6294a90ac104","set_id":"09821e01-1135-e75c-e063-6294a90a3451","openfda":{"nui":["N0000175806","N0000175807"],"unii":["8SKN0B0MIM","F2R8V82B84","J50OIX95QV","T42P99266K","28A37T47QO"],"route":["ORAL"],"rxcui":["1037234","2670308"],"spl_id":["47e8083a-60e6-b517-e063-6294a90ac104"],"brand_name":["URIBEL TABS"],"spl_set_id":["09821e01-1135-e75c-e063-6294a90a3451"],"package_ndc":["0178-0745-01"],"product_ndc":["0178-0745"],"generic_name":["METHENAMINE, BENZOIC ACID, PHENYL SALICYLATE, METHYLENE BLUE, AND HYOSCYAMINE SULFATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["BENZOIC ACID","HYOSCYAMINE SULFATE","METHENAMINE","METHYLENE BLUE","PHENYL SALICYLATE"],"pharm_class_epc":["Nitrogen Binding Agent [EPC]"],"pharm_class_moa":["Ammonium Ion Binding Activity [MoA]"],"manufacturer_name":["Mission Pharmacal Company"],"is_original_packager":[true]},"version":"4","warnings":["WARNINGS Do not exceed recommended dosage. If rapid pulse, dizziness or blurring of vision occurs, discontinue use immediately."],"overdosage":["OVERDOSE Emesis or gastric lavage. Slow intravenous administration of physostigmine in doses of 1 to 4 mg (0.5 to 1 mg in children), repeated as needed in one to two hours to reverse severe antimuscarinic symptoms. Administration of small doses of diazepam to control excitement and seizures. Artificial respiration with oxygen if needed for respiratory depression. Adequate hydration. Symptomatic treatment as necessary. If overdose is suspected, contact your local Poison Control Center or emergency room immediately. US residents can contact the US National Poison Hotline at 1-800-222-1222."],"description":["DESCRIPTION Uribel® Tabs for oral administration Each tablet contains: Methenamine .........................................................................................................................81.6 mg Benzoic Acid ..........................................................................................................................9.0 mg Phenyl Salicylate ...................................................................................................................36.2 mg Methylene Blue ......................................................................................................................10.8 mg Hyoscyamine Sulfate..............................................................................................................0.12 mg HYOSCYAMINE SULFATE. [620-61-1][3(S)-endo]-α-(Hydroxymethyl)-benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester sulfate(2:1)(salt); 1αH, 5αH-tropan-3α-ol(-)- tropate(ester) sulfate(2:1)(salt); 3α-tropanyl S-(-)-tropate; I-tropic acid ester with tropine; I-tropine tropate. C 34 H 48 N 2 O 10 S. Hyoscyamine Sulfate is an alkaloid of belladonna. Exists as a white crystalline powder. Its solutions are alkaline to litmus. Affected by light, it is slightly soluble in water; freely soluble in alcohol; sparingly soluble in ether. METHENAMINE. [100-97-0] 1,3,5,7-Tetraazatricyclo [3.3.1.-1 3,7] decane; hexamethylenetetramine; HMT; HMTA; hexamine; 1,3,5,7-tetraazaadamantane hexamethyleneimine; Uritone; Urotropin. C 6 H 12 N 4 ; mol wt 140.19; C 51.40%, H 8.63%, N 39.96%. Methenamine (hexamethylenetetramine) exists as colorless, lustrous crystals or white crystalline powder. Its solutions are alkaline to litmus. Freely soluble in water, soluble in alcohol and in chloroform. METHYLENE BLUE. [61-73-4] 3,7-Bis(dimethylamino) phenothiazin-5-ium chloride; C.I. Basic Blue 9; methylthioninium chloride; tetramethylthionine chloride; 3,7-bis(dimethylamino) phenazathionium chloride. C 16 H 18 ClN 3 S; mol wt 319.85, C 60.08%, H 5.67%, Cl 11.08%, N 13.14%, S 10.03%. Methylene Blue (Methylthionine chloride) exists as dark green crystals. It is soluble in water and in chloroform; sparingly soluble in alcohol. PHENYL SALICYLATE. [118-55-8] 2-Hydroxybenzoic acid phenyl ester; Salol. C 13 H 10 O 3 ; mol wt 214.22, C 72.89%, H 4.71%, O 22.41%. Made by the action of phosphorus oxychloride on a mixture of phenol and salicylic acid. Phenyl Salicylate exists as white crystals with a melting point of 41°-43°C. It is very slightly soluble in water and freely soluble in alcohol. BENZOIC ACID. [65-85-0] Benzenecarboxylic acid; Benzeneformic acid; Benzenemethanoic acid. C 7 H 6 O 2 ; mol wt 122.12, C 68.85%, H 4.95%, O 26.20%. Exists as white powder or crystals, scales or needles. It has a strong odor and is slightly soluble in alcohol; also soluble in volatile and fixed oils, slightly soluble in petroleum ether. Uribel Tabs contain inactive ingredients: Crospovidone, FD&C Blue #2, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Glycol, Polyvinyl Alcohol, Rice Starch, Silicon Dioxide, Sodium Starch Glycolate, Stearic Acid, Talc, and Titanium Dioxide."],"precautions":["PRECAUTIONS Cross sensitivity and/or related problems Patients intolerant of belladonna alkaloids or salicylates may be intolerant of this medication also. Delay in gastric emptying could complicate the management of gastric ulcers. Pregnancy/Reproduction (FDA Pregnancy Category C) Hyoscyamine and methenamine cross the placenta. Studies concerning the effect of hyoscyamine and methenamine on pregnancy and reproduction have not been done in animals or humans. Thus, it is not known whether Uribel Tabs cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Uribel Tabs should be given to a pregnant woman only if clearly needed. Breastfeeding Problems in humans have not been documented; however, methenamine and traces of hyoscyamine are excreted in breast milk. Accordingly, Uribel Tabs should be given to a nursing mother with caution and only if clearly needed. Prolonged use There have been no studies to establish the safety of prolonged use in humans. No known long-term animal studies have been performed to evaluate carcinogenic potential. Pediatric use Infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids. Geriatric use Use with caution in elderly patients as they may respond to usual doses of hyoscyamine with excitement, agitation, drowsiness or confusion. ADVERSE REACTIONS Cardiovascular: rapid heartbeat, flushing Central Nervous System: blurred vision, dizziness, drowsiness Genitourinary: difficult micturition, acute urinary retention Gastrointestinal: dry mouth, nausea and vomiting Respiratory: shortness of breath or trouble breathing Serious allergic reactions to this drug are rare. Seek immediate medical attention if you notice symptoms of a serious allergic reaction, including itching, rash, severe dizziness, swelling or trouble breathing. This medication can cause urine and sometimes stools to turn blue to blue-green. This effect is harmless and will subside after medication is stopped. Call your doctor or physician for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Mission Pharmacal at 1-800-298-1087 or FDA at 1-800-FDA-1088, www.fda.gov/medwatch. Drug interactions As a result of hyoscyamine's effects on gastrointestinal motility and gastric emptying, absorption of other oral medications may be decreased during concurrent use with this combination medication. Methylene blue inhibits a range of CYP isozymes in vitro, including 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5. This interaction could be more pronounced with narrow therapeutic index drugs that are metabolized by one of these enzymes (e.g., digoxin, warfarin, phenytoin, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus). However, the clinical relevance of these in vitro interactions is unknown. Urinary alkalizers and thiazide diuretics May cause the urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde. Antimuscarinics: Concurrent use may intensify antimuscarinic effects of hyoscyamine because of secondary antimuscarinic activities of these medications. Antacids/antidiarrheals Concurrent use may reduce absorption of hyoscyamine resulting in decreased therapeutic effectiveness. Concurrent use with antacids may cause urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde. Doses of these medications should be spaced 1 hour apart from doses of hyoscyamine. Antimyasthenics Concurrent use with hyoscyamine may further reduce intestinal motility, therefore, caution is recommended. Ketoconazole and hyoscyamine may cause increased gastrointestinal pH. Concurrent administration with hyoscyamine may result in marked reduction in the absorption of ketoconazole. Patients should be advised to take this combination at least 2 hours after ketoconazole. Monoamine oxidase (MAO) inhibitors Concurrent use with hyoscyamine may intensify antimuscarinic side effects. Opioid (narcotic) analgesics may result in increased risk of severe constipation. Sulfonamides These drugs may precipitate with formaldehyde in the urine increasing the danger of crystalluria. Patients should be advised that the urine and/or stools may become blue to blue-green as a result of the excretion of methylene blue."],"how_supplied":["HOW SUPPLIED Uribel Tabs are blue tablets imprinted with “SAT” on one side and “109” on opposite side. NDC 0178-0745-01, bottle of 100 tablets."],"effective_time":"20260108","contraindications":["CONTRADICTIONS Hypersensitivity to any of the ingredients is possible. Risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy)."],"storage_and_handling":["STORAGE Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure. Store at controlled room temperature 20°-25°C (68°- 77°F). Keep in a cool, dry place. Keep container tightly closed. Keep this and all drugs out of reach of children."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY HYOSCYAMINE SULFATE is a parasympatholytic which relaxes smooth muscles and thus produces an antispasmodic effect. It is well absorbed from the gastrointestinal tract and is rapidly distributed throughout the body tissues. Most is excreted in the urine within 12 hours, 13% to 50% being unchanged. Its biotransformation is hepatic. Its protein binding is moderate. METHENAMINE degrades in an acidic urine environment releasing formaldehyde which provides bactericidal or bacteriostatic action. It is well absorbed from the gastrointestinal tract. 70%-90% reaches the urine unchanged at which point it is hydrolyzed if the urine is acidic. Within 24 hours it is almost completely (90%) excreted; of this at a pH of 5, approximately 20% is formaldehyde. Protein binding - some formaldehyde is bound to substances in the urine and surrounding tissues. Methenamine is freely distributed to body tissue and fluids but is not clinically significant as it does not hydrolyze at pH greater than 6.8. METHYLENE BLUE possesses weak antiseptic properties. It is well absorbed by the gastrointestinal tract and rapidly reduced to leukomethylene blue which is stabilized in some combination form in the urine. 75% is excreted unchanged. PHENYL SALICYLATE releases salicylate, a mild analgesic for pain. BENZOIC ACID helps maintain an acid pH in the urine necessary for the degradation of methenamine."],"indications_and_usage":["INDICATIONS AND USAGE Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."],"spl_unclassified_section":["URIBEL TABS Rx Only 100 Tablets"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Adults One tablet orally 4 times per day followed by liberal fluid intake. Older Children Dosage must be individualized by physician. Not recommended for use in children six years of age or younger."],"drug_abuse_and_dependence":["DRUG ABUSE AND DEPENDENCE A dependence on the use of Uribel Tabs has not been reported and due to the nature of its ingredients, abuse of Uribel Tabs is not expected."],"spl_product_data_elements":["URIBEL TABS Methenamine, Benzoic Acid, Phenyl Salicylate, Methylene Blue, and Hyoscyamine Sulfate POLYETHYLENE GLYCOL, UNSPECIFIED POLYVINYL ALCOHOL, UNSPECIFIED SODIUM STARCH GLYCOLATE TYPE A POTATO TITANIUM DIOXIDE CELLULOSE, MICROCRYSTALLINE TALC MAGNESIUM STEARATE SILICON DIOXIDE STEARIC ACID STARCH, RICE CROSPOVIDONE HYOSCYAMINE SULFATE HYOSCYAMINE PHENYL SALICYLATE PHENYL SALICYLATE METHENAMINE METHENAMINE METHYLENE BLUE METHYLENE BLUE CATION BENZOIC ACID BENZOIC ACID SAT;109"],"package_label_principal_display_panel":["PACKAGE LABEL Rx Only UBL030R1023 Distributed by: MISSION PHARMACAL COMPANY San Antonio, TX 78230 1355 R0823 label"]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"SEROTONIN SYNDROME","source":"FDA FAERS","actionTaken":"Reported 511 times"},{"date":"","signal":"DRUG INTERACTION","source":"FDA FAERS","actionTaken":"Reported 398 times"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"Reported 285 times"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"Reported 207 times"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"Reported 182 times"},{"date":"","signal":"TOXICITY TO VARIOUS AGENTS","source":"FDA FAERS","actionTaken":"Reported 138 times"},{"date":"","signal":"OVERDOSE","source":"FDA FAERS","actionTaken":"Reported 99 times"},{"date":"","signal":"INTENTIONAL OVERDOSE","source":"FDA FAERS","actionTaken":"Reported 94 times"},{"date":"","signal":"ENCEPHALOPATHY","source":"FDA FAERS","actionTaken":"Reported 91 times"},{"date":"","signal":"CONFUSIONAL STATE","source":"FDA FAERS","actionTaken":"Reported 81 times"}],"drugInteractions":[{"name":"Alpha/Beta Agonists","source":"DrugCentral","severity":"Potentially significant","description":"MAO Inhibitors may enhance the hypertensive effect of Alpha/Beta-Agonists"},{"name":"Amphetamines","source":"DrugCentral","severity":"Potentially significant","description":"MAO Inhibitors may enhance the hypertensive effect of amphetamines"},{"name":"Indirectly Acting Sympathomimetic Amines","source":"DrugCentral","severity":"Contraindicated","description":"potentially fatal hypertensive crisis"},{"name":"Selective Serotonin Reuptake Inhibitors","source":"DrugCentral","severity":"Contraindicated","description":"serotonin syndrome"},{"name":"Serotonin/Norepinephrine Reuptake Inhibitors","source":"DrugCentral","severity":"Contraindicated","description":"serotonin syndrome"},{"name":"Tricyclic Antidepressants","source":"DrugCentral","severity":"Contraindicated","description":"very toxic and sometimes fatal reactions the serotonin syndrome or similar"},{"name":"almotriptan","source":"DrugCentral","severity":"Critical","description":"ALMOTRIPTAN/METHYLENE BLUE [VA Drug Interaction]"},{"name":"bupivacaine","source":"DrugCentral","severity":"Critical","description":"BUPIVACAINE/METHYLENE BLUE [VA Drug Interaction]"},{"name":"buspirone","source":"DrugCentral","severity":"Potentially significant","description":"May increase blood pressure"},{"name":"dextromethorphan","source":"DrugCentral","severity":"Contraindicated","description":"fatal/non-fatal reactions"},{"name":"eletriptan","source":"DrugCentral","severity":"Critical","description":"ELETRIPTAN/METHYLENE BLUE [VA Drug Interaction]"},{"name":"frovatriptan","source":"DrugCentral","severity":"Critical","description":"FROVATRIPTAN/METHYLENE BLUE [VA Drug Interaction]"},{"name":"isocarboxazid","source":"DrugCentral","severity":"Critical","description":"ISOCARBOXAZID/METHYLENE BLUE [VA Drug Interaction]"},{"name":"levodopa","source":"DrugCentral","severity":"Contraindicated","description":"life-threatening hypertensive reaction"},{"name":"linezolid","source":"DrugCentral","severity":"Critical","description":"LINEZOLID/METHYLENE BLUE [VA Drug Interaction]"},{"name":"mepivacaine","source":"DrugCentral","severity":"Critical","description":"MEPIVACAINE/METHYLENE BLUE [VA Drug Interaction]"},{"name":"methyldopa","source":"DrugCentral","severity":"Potentially significant","description":"hypertension may occur"},{"name":"mirtazapine","source":"DrugCentral","severity":"Contraindicated","description":"Label warning"},{"name":"naratriptan","source":"DrugCentral","severity":"Critical","description":"METHYLENE BLUE/NARATRIPTAN HYDROCHLORIDE [VA Drug Interaction]"},{"name":"pargyline","source":"DrugCentral","severity":"Critical","description":"METHYLENE BLUE/PARGYLINE [VA Drug Interaction]"}],"commonSideEffects":[{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypokalemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypomagnesemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Myoclonus","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Seizure-like phenomena","drugRate":"","severity":"common","organSystem":""},{"effect":"Palpitations","drugRate":"","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"","severity":"common","organSystem":""},{"effect":"Eye pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Ocular hyperemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Vision blurred","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain lower","drugRate":"","severity":"common","organSystem":""},{"effect":"Dry mouth","drugRate":"","severity":"common","organSystem":""},{"effect":"Flatulence","drugRate":"","severity":"common","organSystem":""},{"effect":"Glossodynia","drugRate":"","severity":"common","organSystem":""},{"effect":"Tongue eruption","drugRate":"","severity":"common","organSystem":""},{"effect":"Thirst","drugRate":"","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"","severity":"common","organSystem":""},{"effect":"Dysuria","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Achalasia of esophagus","Acute nephropathy","Anemia","Anemia due to enzyme deficiency","Atony of colon","Benign prostatic hyperplasia","Bladder outflow obstruction","Blood coagulation disorder","Body fluid retention","Breastfeeding (mother)","Cardiovascular event risk","Chronic heart failure","Cirrhosis of liver","Conduction disorder of the heart","Deficiency of glucose-6-phosphate dehydrogenase","Diabetes mellitus","Disease of liver","Disorder of autonomic nervous system","Disorder of cardiovascular system","Disorder of coronary artery"],"specialPopulations":{"Pregnancy":"","Geriatric use":"","Paediatric use":"Not recommended for use in children six years of age or younger.","Renal impairment":"","Hepatic impairment":""},"seriousAdverseEvents":[{"effect":"Seizure-like phenomenon","drugRate":"4.2%","severity":"serious"},{"effect":"Serotonin syndrome","drugRate":"","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Hemolytic anemia","drugRate":"","severity":"serious"},{"effect":"Hemolysis","drugRate":"","severity":"serious"},{"effect":"Hyperbilirubinemia","drugRate":"","severity":"serious"},{"effect":"Death","drugRate":"","severity":"serious"},{"effect":"Infusion site extravasation","drugRate":"","severity":"serious"},{"effect":"Elevated liver enzymes","drugRate":"","severity":"serious"},{"effect":"Necrotic ulcer","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["methylthioninium chloride","methylthioninium"],"patents":[],"pricing":[],"_recalls":[{"date":"20180815","reason":"Lack of sterility assurance.","classification":"Class II"},{"date":"20251015","reason":"Lack of Assurance of Sterility","classification":"Class II"},{"date":"20180117","reason":"Labeling: Incorrect or Missing Lot and/or Exp Date: Beyond Use Date (BUD) exceed the BUD/EXP of at least one ingredient used to make final product.","classification":"Class II"},{"date":"20161207","reason":"CGMP Deviations; deficiencies at the manufacturer  may result in assay or content uniformity failures","classification":"Class II"},{"date":"20200812","reason":"cGMP deviations","classification":"Class II"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=METHYLENE BLUE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:03:22.572165+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:03:28.236534+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:03:22.644306+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METHYLENE BLUE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:03:28.550087+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:03:21.439968+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:03:21.440020+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:03:21.440028+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL550495/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:03:29.879729+00:00"}},"allNames":"methylthioninium benzalkonium chloride hydrate","offLabel":[],"synonyms":["methylthioninium benzalkonium chloride hydrate","methylthioninium chloride hydrate","methylenum coeruleum","methylthioninium chloratum","methylene blue","methylthioninium chloride","aizen methylene blue","proveblue"],"timeline":[{"date":"","type":"positive","milestone":"First FDA approval for irritative voiding symptoms","regulator":"FDA","description":"Initial approval for the treatment of irritative voiding symptoms."},{"date":"","type":"positive","milestone":"First FDA approval for methemoglobinemia","regulator":"FDA","description":"Approval for the treatment of methemoglobinemia."},{"date":"","type":"positive","milestone":"Phase 3 trial completion for septic shock","regulator":"none","description":"Completion of a Phase 3 trial evaluating Methylene Blue in septic shock."},{"date":"","type":"neutral","milestone":"Phase 2 trial initiation for photodynamic therapy for abscesses","regulator":"none","description":"Initiation of a Phase 2 trial for photodynamic therapy in treating abscesses."}],"_dailymed":{"setId":"8c56fbad-a449-4ed4-a55f-1694e4e8e26a","title":"METHYLENE BLUE INJECTION [ZYDUS PHARMACEUTICALS USA INC.]","labeler":""},"aiSummary":"Methylene Blue is a small molecule with a broad range of applications, including the treatment of urinary tract symptoms and methemoglobinemia. It acts by reducing methemoglobin to hemoglobin and has been used for over a century. Key approved indications include irritative voiding symptoms and methemoglobinemia. Clinical differentiation lies in its unique mechanism of action and broad spectrum of use. Commercially, it is a generic drug with limited revenue potential but significant historical importance. Pipeline expansion includes studies in septic shock and photodynamic therapy.","brandName":"Methylthioninium Benzalkonium Chloride Hydrate","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Methemoglobin","novelty":"generic","targets":[{"gene":"MAOA","source":"DrugCentral","target":"Amine oxidase [flavin-containing] A","protein":"Amine oxidase [flavin-containing] A","activityType":"IC50"},{"gene":"MAOB","source":"DrugCentral","target":"Amine oxidase [flavin-containing] B","protein":"Amine oxidase [flavin-containing] B","activityType":"IC50"},{"gene":"APP","source":"DrugCentral","target":"Amyloid beta A4 protein","protein":"Amyloid beta A4 protein","activityType":"IC50"},{"gene":"GSR","source":"DrugCentral","target":"Glutathione reductase, mitochondrial","protein":"Glutathione reductase, mitochondrial","activityType":"IC50"},{"gene":"MAPT","source":"DrugCentral","target":"Microtubule-associated protein tau","protein":"Microtubule-associated protein tau","activityType":"IC50"},{"gene":"TXNRD1","source":"DrugCentral","target":"Thioredoxin reductase 1, cytoplasmic","protein":"Thioredoxin reductase 1, cytoplasmic","activityType":"IC50"}],"modality":"small molecule","drugClass":"Nitrogen Binding Agent [EPC]","explanation":"","oneSentence":"","technicalDetail":"Methylene Blue binds to methemoglobin and facilitates its reduction to hemoglobin through the NADPH-dependent methemoglobin reductase pathway. It also exhibits selective cytotoxicity against certain pathogens and can enhance the efficacy of light-based therapies."},"_scrapedAt":"2026-03-28T00:33:52.078Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"notes":"","yoyGrowth":"","launchDate":"2016","marketShare":"","revenueYear":"","annualCostUS":"Generic pricing varies by manufacturer","_launchSource":"FDA NDA204630 (PROVEPHARM SAS)","genericStatus":"Generic — off-patent","currentRevenue":"","percentOfCompany":"","manufacturerCount":"8 approved manufacturers","patientPopulation":"","peakSalesEstimate":"Not publicly reported","genericCompetition":"yes"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1763","fields":["approvals","synonyms","ATC","pharmacokinetics","patents","indications","contraindications","interactions","targets"],"source":"DrugCentral"},{"id":2,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=METHYLENE BLUE","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=METHYLENE%20BLUE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METHYLENE BLUE","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":6,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/","fields":["timeline","launchDate"],"source":"FDA Drugs@FDA"},{"id":7,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":8,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":9,"url":"https://www.whocc.no/atc_ddd_index/","fields":["classification"],"source":"WHO ATC/DDD Index"},{"id":10,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"},{"id":11,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/","fields":["genericManufacturers"],"source":"FDA Drugs@FDA (ANDA/BLA)"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:03:32.401887+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Methylene Blue","company":"Various","advantage":"Methylene Blue is often used as a diagnostic agent, and its competitors include other diagnostic agents such as Indocyanine Green and Lymphazurin.","genericName":"Methylene Blue"},{"name":"Lymphazurin","company":"Bayer","advantage":"Lymphazurin is used for sentinel lymph node biopsy and competes with Methylene Blue in diagnostic applications.","genericName":"Phthalocyanine Green Trisodium Salt"},{"name":"Indocyanine Green","company":"Akorn","advantage":"Indocyanine Green is used for diagnostic imaging and competes with Methylene Blue in its ability to visualize tissues and organs.","genericName":"Indocyanine Green"},{"name":"Phthalo Blue (BF)","company":"Various","advantage":"Phthalo Blue (BF) is used in various applications including dyeing and printing, and competes with Methylene Blue in its ability to bind to proteins and other molecules.","genericName":"Phthalocyanine Blue"}],"genericName":"methylene blue","indications":{"approved":[{"name":"Diagnosis of methemoglobinemia","regulator":"FDA"},{"name":"Diagnosis of cyanide poisoning","regulator":"FDA"},{"name":"Diagnosis of certain types of anemia","regulator":"FDA"},{"name":"Diagnosis of certain types of poisoning","regulator":"FDA"},{"name":"Diagnosis of certain types of infections","regulator":"FDA"},{"name":"Diagnosis of certain types of tumors","regulator":"FDA"},{"name":"Diagnosis of certain types of eye conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurological conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of psychiatric conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of cardiovascular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of respiratory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of gastrointestinal conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of genitourinary conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of musculoskeletal conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of dermatological conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of allergic conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of immunological conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of infectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of parasitic conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of fungal conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of viral conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of bacterial conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of prion conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of amyloid conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodevelopmental conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuromuscular conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinfectious conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neuroinflammatory conditions","regulator":"FDA"},{"name":"Diagnosis of certain types of neurodegenerative conditions","regulator":"FDA"}],"offLabel":[{"name":"Cyanide poisoning","notes":"Used in emergency settings to treat cyanide poisoning.","evidenceLevel":"strong"}],"pipeline":[{"name":"Septic shock","notes":"","phase":"Phase 3","status":"completed"},{"name":"Photodynamic therapy for abscesses","notes":"","phase":"Phase 2","status":"not_yet_recruiting"}]},"_drugCentral":{"patents":[],"targets":[{"gene":"MAOA","target":"Amine oxidase [flavin-containing] A","protein":"Amine oxidase [flavin-containing] A","activityType":"IC50","activityUnit":"","activityValue":7.15},{"gene":"MAOB","target":"Amine oxidase [flavin-containing] B","protein":"Amine oxidase [flavin-containing] B","activityType":"IC50","activityUnit":"","activityValue":5.36},{"gene":"APP","target":"Amyloid beta A4 protein","protein":"Amyloid beta A4 protein","activityType":"IC50","activityUnit":"","activityValue":6.26},{"gene":"GSR","target":"Glutathione reductase, mitochondrial","protein":"Glutathione reductase, mitochondrial","activityType":"IC50","activityUnit":"","activityValue":4.8},{"gene":"MAPT","target":"Microtubule-associated protein tau","protein":"Microtubule-associated protein tau","activityType":"IC50","activityUnit":"","activityValue":5.72},{"gene":"TXNRD1","target":"Thioredoxin reductase 1, cytoplasmic","protein":"Thioredoxin reductase 1, cytoplasmic","activityType":"IC50","activityUnit":"","activityValue":4.52}],"atcCodes":["V03AB17","V04CG05"],"synonyms":["methylthioninium benzalkonium chloride hydrate","methylthioninium chloride hydrate","methylenum coeruleum","methylthioninium chloratum","methylene blue","methylthioninium chloride","aizen methylene blue","proveblue"],"approvals":[{"date":"","orphan":false,"company":"","regulator":"FDA"}],"properties":{},"drugClasses":["Monoamine Oxidase Inhibitors","methylthioninium chloride"],"identifiers":{"NUI":"N0000146895","MMSL":"1036","NDDF":"001094","UNII":"T42P99266K","VUID":"4018579","CHEBI":"CHEBI:6872","VANDF":"4018579","RXNORM":"6878","UMLSCUI":"C0025746","ChEMBL_ID":"CHEMBL550495","KEGG_DRUG":"D02312","DRUGBANK_ID":"DB09241","PDB_CHEM_ID":" MBT","PUBCHEM_CID":"6099","SNOMEDCT_US":"354064008","SECONDARY_CAS_RN":"7220-79-3","MESH_DESCRIPTOR_UI":"D008751"},"indications":[{"name":"Methemoglobinemia","source":"DrugCentral","umlsCui":"C0025637","snomedId":38959009}],"formulations":[{"form":"CAPSULE","route":"ORAL","status":"Unapproved drug other","tradeName":"URO-SP"},{"form":"CAPSULE","route":"ORAL","status":"unapproved drug other","tradeName":"URIBEL"},{"form":"CAPSULE","route":"ORAL","status":"unapproved drug other","tradeName":"URIMAR-T CAPS"},{"form":"CAPSULE","route":"ORAL","status":"unapproved drug other","tradeName":"UrNeva"},{"form":"CAPSULE","route":"ORAL","status":"unapproved drug other","tradeName":"Uro-MP"},{"form":"CAPSULE","route":"ORAL","status":"unapproved drug other","tradeName":"UroAv-B"},{"form":"CAPSULE","route":"ORAL","status":"unapproved drug other","tradeName":"Ustell"},{"form":"INJECTION","route":"INTRAVENOUS","status":"NDA","tradeName":"PROVAYBLUE"},{"form":"INJECTION","route":"INTRAVENOUS","status":"unapproved drug other","tradeName":"Methylene Blue"},{"form":"TABLET","route":"ORAL","status":"Unapproved drug other","tradeName":"URELLE"}],"offLabelUses":[],"drugCentralId":1763,"drugInteractions":[{"risk":"Potentially significant","description":"MAO Inhibitors may enhance the hypertensive effect of Alpha/Beta-Agonists","interactingClass":"Alpha/Beta Agonists"},{"risk":"Potentially significant","description":"MAO Inhibitors may enhance the hypertensive effect of amphetamines","interactingClass":"Amphetamines"},{"risk":"Contraindicated","description":"potentially fatal hypertensive crisis","interactingClass":"Indirectly Acting Sympathomimetic Amines"},{"risk":"Contraindicated","description":"serotonin syndrome","interactingClass":"Selective Serotonin Reuptake Inhibitors"},{"risk":"Contraindicated","description":"serotonin syndrome","interactingClass":"Serotonin/Norepinephrine Reuptake Inhibitors"},{"risk":"Contraindicated","description":"very toxic and sometimes fatal reactions the serotonin syndrome or similar","interactingClass":"Tricyclic Antidepressants"},{"risk":"Critical","description":"ALMOTRIPTAN/METHYLENE BLUE [VA Drug Interaction]","interactingClass":"almotriptan"},{"risk":"Critical","description":"BUPIVACAINE/METHYLENE BLUE [VA Drug Interaction]","interactingClass":"bupivacaine"},{"risk":"Potentially significant","description":"May increase blood pressure","interactingClass":"buspirone"},{"risk":"Contraindicated","description":"fatal/non-fatal reactions","interactingClass":"dextromethorphan"},{"risk":"Critical","description":"ELETRIPTAN/METHYLENE BLUE [VA Drug Interaction]","interactingClass":"eletriptan"},{"risk":"Critical","description":"FROVATRIPTAN/METHYLENE BLUE [VA Drug Interaction]","interactingClass":"frovatriptan"},{"risk":"Critical","description":"ISOCARBOXAZID/METHYLENE BLUE [VA Drug Interaction]","interactingClass":"isocarboxazid"},{"risk":"Contraindicated","description":"life-threatening hypertensive reaction","interactingClass":"levodopa"},{"risk":"Critical","description":"LINEZOLID/METHYLENE BLUE [VA Drug Interaction]","interactingClass":"linezolid"},{"risk":"Critical","description":"MEPIVACAINE/METHYLENE BLUE [VA Drug Interaction]","interactingClass":"mepivacaine"},{"risk":"Potentially significant","description":"hypertension may occur","interactingClass":"methyldopa"},{"risk":"Contraindicated","description":"Label warning","interactingClass":"mirtazapine"},{"risk":"Critical","description":"METHYLENE BLUE/NARATRIPTAN HYDROCHLORIDE [VA Drug Interaction]","interactingClass":"naratriptan"},{"risk":"Critical","description":"METHYLENE BLUE/PARGYLINE [VA Drug Interaction]","interactingClass":"pargyline"}],"contraindications":[{"name":"Achalasia of esophagus","source":"DrugCentral","umlsCui":"C0014848","snomedId":45564002},{"name":"Acute nephropathy","source":"DrugCentral","umlsCui":"C0268734","snomedId":58574008},{"name":"Anemia","source":"DrugCentral","umlsCui":"C0002871","snomedId":271737000},{"name":"Anemia due to enzyme deficiency","source":"DrugCentral","umlsCui":"C0272053","snomedId":111577008},{"name":"Atony of colon","source":"DrugCentral","umlsCui":"C0267516","snomedId":29479008},{"name":"Benign prostatic hyperplasia","source":"DrugCentral","umlsCui":"C1739363","snomedId":266569009},{"name":"Bladder outflow obstruction","source":"DrugCentral","umlsCui":"C0403654","snomedId":236645006},{"name":"Blood coagulation disorder","source":"DrugCentral","umlsCui":"C0005779","snomedId":64779008},{"name":"Body fluid retention","source":"DrugCentral","umlsCui":"C0268000","snomedId":43498006},{"name":"Breastfeeding (mother)","source":"DrugCentral","umlsCui":"C1623040","snomedId":413712001},{"name":"Cardiovascular event risk","source":"DrugCentral","umlsCui":"C1273410","snomedId":395112001},{"name":"Chronic heart failure","source":"DrugCentral","umlsCui":"C0264716","snomedId":48447003},{"name":"Cirrhosis of liver","source":"DrugCentral","umlsCui":"C0023890","snomedId":19943007},{"name":"Conduction disorder of the heart","source":"DrugCentral","umlsCui":"C0264886","snomedId":44808001},{"name":"Deficiency of glucose-6-phosphate dehydrogenase","source":"DrugCentral","umlsCui":"C2939465","snomedId":124134002},{"name":"Diabetes mellitus","source":"DrugCentral","umlsCui":"C0011849","snomedId":73211009},{"name":"Disease of liver","source":"DrugCentral","umlsCui":"C0023895","snomedId":235856003},{"name":"Disorder of autonomic nervous system","source":"DrugCentral","umlsCui":"C1145628","snomedId":15241006},{"name":"Disorder of cardiovascular system","source":"DrugCentral","umlsCui":"C0007222","snomedId":49601007},{"name":"Disorder of coronary artery","source":"DrugCentral","umlsCui":"C1956346","snomedId":414024009},{"name":"Edema","source":"DrugCentral","umlsCui":"C0013604","snomedId":267038008},{"name":"Factor II deficiency","source":"DrugCentral","umlsCui":"C3203356","snomedId":73975000},{"name":"Fever greater than 100.4 Fahrenheit","source":"DrugCentral","umlsCui":"C1959900","snomedId":426000000},{"name":"Gastritis","source":"DrugCentral","umlsCui":"C0017152","snomedId":4556007},{"name":"Gastroesophageal reflux disease","source":"DrugCentral","umlsCui":"C0017168","snomedId":235595009},{"name":"Gastrointestinal hemorrhage","source":"DrugCentral","umlsCui":"C0017181","snomedId":74474003},{"name":"Gastrointestinal ulcer","source":"DrugCentral","umlsCui":"C0237938","snomedId":40845000},{"name":"Glaucoma","source":"DrugCentral","umlsCui":"C0017601","snomedId":23986001},{"name":"Hemophilia","source":"DrugCentral","umlsCui":"C0684275","snomedId":90935002},{"name":"Hepatic failure","source":"DrugCentral","umlsCui":"C0085605","snomedId":59927004},{"name":"Hiatal hernia","source":"DrugCentral","umlsCui":"C3489393","snomedId":84089009},{"name":"Hypernatremia","source":"DrugCentral","umlsCui":"C0020488","snomedId":39355002},{"name":"Hyperphosphatemia","source":"DrugCentral","umlsCui":"C0085681","snomedId":20165001},{"name":"Hypertensive disorder","source":"DrugCentral","umlsCui":"C0020538","snomedId":38341003},{"name":"Hyperthyroidism","source":"DrugCentral","umlsCui":"C0020550","snomedId":34486009},{"name":"Hypocalcemia","source":"DrugCentral","umlsCui":"C0020598","snomedId":5291005},{"name":"Hypovolemic shock","source":"DrugCentral","umlsCui":"C0020683","snomedId":39419009},{"name":"Kidney disease","source":"DrugCentral","umlsCui":"C0022658","snomedId":90708001},{"name":"Liver function tests abnormal","source":"DrugCentral","umlsCui":"C0151766","snomedId":166603001},{"name":"Myasthenia gravis","source":"DrugCentral","umlsCui":"C0026896","snomedId":91637004},{"name":"Nasal polyp","source":"DrugCentral","umlsCui":"C0027430","snomedId":52756005},{"name":"Paralytic ileus","source":"DrugCentral","umlsCui":"C0030446","snomedId":55525008},{"name":"Pregnancy, function","source":"DrugCentral","umlsCui":"C0032961","snomedId":289908002},{"name":"Pyloric obstruction","source":"DrugCentral","umlsCui":"C1541124","snomedId":244815007},{"name":"Severe chronic ulcerative colitis","source":"DrugCentral","umlsCui":"C0267387","snomedId":14311001},{"name":"Severe dehydration","source":"DrugCentral","umlsCui":"C3472181","snomedId":450316000},{"name":"Thrombotic thrombocytopenic purpura","source":"DrugCentral","umlsCui":"C0034155","snomedId":78129009},{"name":"Thyrotoxicosis","source":"DrugCentral","umlsCui":"C0040156","snomedId":90739004},{"name":"Toxic megacolon","source":"DrugCentral","umlsCui":"C0025162","snomedId":28536002},{"name":"Vitamin K deficiency","source":"DrugCentral","umlsCui":"C0042880","snomedId":52675005}]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[{"name":"CardCare","slug":"echinacea-hypericum-valeriana-aconitum-nap.-arsenicum-alb.-aur.-met.-baryta-carb.-benzoicum-ac.-berber.-vulg.-bryonia-calc.-fluor.-cantharis-ceanothus-chelidonium-maj.-chionanthus-cinchona-convallaria-crotalus-hor.-digitalis-gelsemium-glonoinum-hydrofluoricum-ac.-kali-iod.-lachesis-lycopus-naja-nux-vom.-phos.-pulsatilla-rhus-tox.-vipera-elaps.","company":"Newton Laboratories, Inc.","genericName":"ECHINACEA, HYPERICUM, VALERIANA, ACONITUM NAP., ARSENICUM ALB., AUR. MET., BARYTA CARB., BENZOICUM AC., BERBER. VULG., BRYONIA, CALC. FLUOR., CANTHARIS, CEANOTHUS, CHELIDONIUM MAJ., CHIONANTHUS, CINCHONA, CONVALLARIA, CROTALUS HOR., DIGITALIS, GELSEMIUM, GLONOINUM, HYDROFLUORICUM AC. KALI IOD., LACHESIS, LYCOPUS, NAJA, NUX VOM., PHOS., PULSATILLA, RHUS TOX., VIPERA, ELAPS.","relationship":"same-class"},{"name":"URIBEL TABS","slug":"methenamine-benzoic-acid-phenyl-salicylate-methylene-blue-and-hyoscyamine-sulfate","company":"Mission Pharmacal Company","genericName":"METHENAMINE, BENZOIC ACID, PHENYL SALICYLATE, METHYLENE BLUE, AND HYOSCYAMINE SULFATE","relationship":"same-class"},{"name":"RENELIX","slug":"benzoic-acid-nitric-acid-apis-mellifera-berberis-vulgaris-root-bark-colchicum-autumnale-bulb-protortonia-cacti-solidago-virgaurea-flowering-top-and-capsella-bursa-pastoris-top","company":"PEKANA Naturheilmittel GmbH","genericName":"BENZOIC ACID, NITRIC ACID, APIS MELLIFERA, BERBERIS VULGARIS ROOT BARK, COLCHICUM AUTUMNALE BULB, PROTORTONIA CACTI, SOLIDAGO VIRGAUREA FLOWERING TOP, AND CAPSELLA BURSA-PASTORIS TOP","relationship":"same-class"},{"name":"BENZOICUM ACIDUM","slug":"benzoic-acid","company":"Boiron","genericName":"BENZOIC ACID","relationship":"same-class"},{"name":"Renapath","slug":"benzoicum-acidum-berberis-vulgaris-bryonia-dna-eupatorium-purpureum-glandula-suprarenalis-suis-hydrangea-arborescens-hypothalamus-mercurius-corrosivus-pancreas-suis-pareira-brava-petroselinum-sativum-pituitarum-posterium-rubia-tinctorum-sarsaparilla-solidago-virgaurea-thyroidinum-(bovine)-uva-ursi","company":"Energetix Corporation","genericName":"BENZOICUM ACIDUM, BERBERIS VULGARIS, BRYONIA, DNA, EUPATORIUM PURPUREUM, GLANDULA SUPRARENALIS SUIS, HYDRANGEA ARBORESCENS, HYPOTHALAMUS, MERCURIUS CORROSIVUS, PANCREAS SUIS, PAREIRA BRAVA, PETROSELINUM SATIVUM, PITUITARUM POSTERIUM, RUBIA TINCTORUM, SARSAPARILLA, SOLIDAGO VIRGAUREA, THYROIDINUM (BOVINE), UVA-URSI","relationship":"same-class"},{"name":"Arnica Combination 9208","slug":"arnica-combination","company":"Professional Complementary Health Formulas","genericName":"ARNICA COMBINATION","relationship":"same-class"},{"name":"HKI","slug":"atropinum-sulphuricum-benzoicum-acidum-berberis-vulgaris-calcarea-carbonica-colocynthis-coccus-cacti-lapis-albus-lithium-carbonicum-lycopodium-clavatum-oryctolagus-cuniculus-kidney-rubia-tinctorum-sarsaparilla-urtica-urens","company":"Seroyal USA","genericName":"ATROPINUM SULPHURICUM, BENZOICUM ACIDUM, BERBERIS VULGARIS, CALCAREA CARBONICA, COLOCYNTHIS, COCCUS CACTI, LAPIS ALBUS, LITHIUM CARBONICUM, LYCOPODIUM CLAVATUM, ORYCTOLAGUS CUNICULUS KIDNEY, RUBIA TINCTORUM, SARSAPARILLA, URTICA URENS","relationship":"same-class"},{"name":"Chemstat","slug":"glycerinum-taraxacum-officinale-phytolacca-decandra-arsenicum-album-nitricum-acidum-nux-vomica-petroleum-phosphoricum-acidum-phosphorus-acetylsalicylicum-acidum-glonoinum-insulinum-(human)-lithium-carbonicum-thyroidinum-(suis)-aceticum-acidum-benzoicum-acidum-benzyl-alcohol-boricum-acidum-chlorinum-cortisone-aceticum-eugenol-folliculinum-isopropyl-palmitate-lacticum-acidum-petroleum-jelly-phenyl-butazone-plumbum-metallicum-potassium-sorbate-resorcinum-salicylicum-acidum","company":"Energique, Inc.","genericName":"GLYCERINUM, TARAXACUM OFFICINALE, PHYTOLACCA DECANDRA, ARSENICUM ALBUM, NITRICUM ACIDUM, NUX VOMICA, PETROLEUM, PHOSPHORICUM ACIDUM, PHOSPHORUS, ACETYLSALICYLICUM ACIDUM, GLONOINUM, INSULINUM (HUMAN), LITHIUM CARBONICUM, THYROIDINUM (SUIS), ACETICUM ACIDUM, BENZOICUM ACIDUM, BENZYL ALCOHOL, BORICUM ACIDUM, CHLORINUM, CORTISONE ACETICUM, EUGENOL, FOLLICULINUM, ISOPROPYL PALMITATE, LACTICUM ACIDUM, PETROLEUM JELLY, PHENYL BUTAZONE, PLUMBUM METALLICUM, POTASSIUM SORBATE, RESORCINUM, SALICYLICUM ACIDUM,","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06865638","phase":"NA","title":"Efficacy and Safety of Colorectal Anastomotic Leak Testing","status":"RECRUITING","sponsor":"Nanchong Central Hospital","startDate":"2024-12-22","conditions":"Colorectal Cancer, Leakage Testing, Colorectal Surgery","enrollment":264},{"nctId":"NCT06155812","phase":"PHASE2, PHASE3","title":"Multimodal Vasopressor Strategy in Septic Shock","status":"COMPLETED","sponsor":"University Medical Centre Maribor","startDate":"2023-12-23","conditions":"Shock, Septic","enrollment":79},{"nctId":"NCT07264543","phase":"PHASE2, PHASE3","title":"Early Methylene Blue in the Microhemodynamics of Septic Patients","status":"RECRUITING","sponsor":"Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva","startDate":"2026-01-09","conditions":"Septic Shock, Hypoperfusion","enrollment":50},{"nctId":"NCT07494773","phase":"PHASE1, PHASE2","title":"Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection","status":"NOT_YET_RECRUITING","sponsor":"University of Oklahoma","startDate":"2026-06-01","conditions":"Burns, Wound Infection","enrollment":50},{"nctId":"NCT07352930","phase":"NA","title":"A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-04-01","conditions":"Breast-Conserving Surgery","enrollment":172},{"nctId":"NCT06131281","phase":"NA","title":"Comparing Reduction With ESD- Versus APC-TORe","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stephen Firkins","startDate":"2023-10-02","conditions":"Obesity, Roux-en-y Anastomosis Site, Weight Gain","enrollment":70},{"nctId":"NCT06900140","phase":"PHASE3","title":"Adjunctive Methylene Blue in Septic Shock","status":"COMPLETED","sponsor":"Dr. Shannon M. Fernando","startDate":"2025-06-02","conditions":"Septic Shock","enrollment":50},{"nctId":"NCT07463859","phase":"NA","title":"Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabetes Mellitus","status":"RECRUITING","sponsor":"University of Sao Paulo","startDate":"2026-04-02","conditions":"Type 2 Diabetes, Halitosis, Periodontitis","enrollment":32},{"nctId":"NCT05252000","phase":"NA","title":"Clinical and Microbiologic Outcomes of Adjunctive Antimicrobial Photodynamic Therapy in the Non-surgical and Surgical Treatment of Teeth With Periodontal Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-04-26","conditions":"Periodontal Diseases","enrollment":20},{"nctId":"NCT06702878","phase":"PHASE3","title":"Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections","status":"RECRUITING","sponsor":"Ondine Biomedical Inc.","startDate":"2024-12-27","conditions":"Surgical Site Infections, Surgical Wound Infection, Infections","enrollment":4514},{"nctId":"NCT07448129","phase":"NA","title":"Clinical Trial to Evaluate the Efficacy and Safety of SUBMO® as a Submucosal Injection Agent in Endoscopic Resection of Superficial Gastrointestinal Lesions.","status":"NOT_YET_RECRUITING","sponsor":"i+Med S.Coop.","startDate":"2026-03","conditions":"Colorectal Polyps","enrollment":300},{"nctId":"NCT07189858","phase":"NA","title":"Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada","status":"RECRUITING","sponsor":"Ondine Biomedical Inc.","startDate":"2026-01-13","conditions":"Surgical Site Infections, Infections, Surgical Wound Infections","enrollment":4740},{"nctId":"NCT05570448","phase":"NA","title":"Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)","status":"RECRUITING","sponsor":"Midwest Veterans' Biomedical Research Foundation","startDate":"2022-02-15","conditions":"Gastro Esophageal Reflux","enrollment":36},{"nctId":"NCT06426550","phase":"NA","title":"Clinical and Microbiological Evaluation of Laser Therapy in the Treatment of Periodontal Disease in Stages III and IV","status":"COMPLETED","sponsor":"Universidade Federal Fluminense","startDate":"2024-05-06","conditions":"Periodontitis, Periodontitis, Adult","enrollment":20},{"nctId":"NCT07437716","phase":"NA","title":"Impact Of Laparoscopic Sleeve Gastrectomy On Obesity-Related Comorbidities In Patients Over 65 Years","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2023-01-01","conditions":"Laparascopic Sleeve Gastrectomy, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT07435415","phase":"EARLY_PHASE1","title":"Local Injection Methylene Blue Combined With Radiation in HNSCC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"China Medical University Hospital","startDate":"2025-08-01","conditions":"Head and Neck Cancer, Local Recurrent Tumor","enrollment":10},{"nctId":"NCT06416462","phase":"NA","title":"Action of Photodynamic Therapy on Wound Quality and Tissue Repair in the Diabetic Foot","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2024-07-30","conditions":"Diabetic Foot Ulcer","enrollment":94},{"nctId":"NCT04234971","phase":"PHASE4","title":"Cost Effectiveness in Alveolar Bone Grafting in Patients With Cleft Lip and Palate","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-06-14","conditions":"Cleft Lip and Palate","enrollment":40},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT06810882","phase":"NA","title":"Intravenous Versus Perineural Ondansetron for Laparoscopic Sleeve Gastrectomy","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-02-16","conditions":"Ondansetron, Laparoscopic, Gastrectomy","enrollment":170},{"nctId":"NCT06052956","phase":"PHASE2","title":"Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses","status":"NOT_YET_RECRUITING","sponsor":"University of Rochester","startDate":"2026-07-15","conditions":"Abscess","enrollment":120},{"nctId":"NCT07395388","phase":"NA","title":"Intraoperative Methylene Blue Spray for the Identification and Preservation of Vital Structures in Thyroidectomy","status":"COMPLETED","sponsor":"Services Hospital, Lahore","startDate":"2022-01-10","conditions":"Benign Multinodular Goiter, Thyroidectomy, Recurrent Laryngeal Nerve Injury","enrollment":136},{"nctId":"NCT06532240","phase":"PHASE3","title":"Methylene Blue for the Treatment of Septic Shock","status":"COMPLETED","sponsor":"Northern Jiangsu People's Hospital","startDate":"2024-08-05","conditions":"Septic Shock","enrollment":88},{"nctId":"NCT04073706","phase":"PHASE3","title":"Sentinel Node Biopsy in Endometrial Cancer","status":"RECRUITING","sponsor":"Queensland Centre for Gynaecological Cancer","startDate":"2021-01-18","conditions":"Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery","enrollment":760},{"nctId":"NCT07373015","phase":"NA","title":"Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-01-01","conditions":"Rectal Neuroendocrine Tumors","enrollment":118},{"nctId":"NCT07040540","phase":"","title":"Hemodynamic Effects of Intradermal Methylene Blue During Breast Surgery Under General Anesthesia","status":"COMPLETED","sponsor":"Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital","startDate":"2025-07-01","conditions":"Breast Cancer, Breast Surgery, Sentinel Lymph Node Biopsy","enrollment":220},{"nctId":"NCT04854005","phase":"","title":"Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-20","conditions":"Breast Cancer","enrollment":78},{"nctId":"NCT07324954","phase":"PHASE1","title":"Methylene Blue in Total Knee Arthroplasty (TKA)","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-02-01","conditions":"Total Knee Arthroplasty, Prosthetic-joint Infection, Irrigation","enrollment":20},{"nctId":"NCT07311057","phase":"PHASE3","title":"Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy","status":"ENROLLING_BY_INVITATION","sponsor":"Daryoush Hamidi Alamdari, PhD","startDate":"2025-12-20","conditions":"SCC - Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma of Skin, Inoperable Disease","enrollment":20},{"nctId":"NCT07311070","phase":"PHASE3","title":"Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue","status":"ENROLLING_BY_INVITATION","sponsor":"Daryoush Hamidi Alamdari, PhD","startDate":"2025-10-21","conditions":"Advanced Basal Cell Carcinoma (BCC), Inoperable Disease, Morpheaform Basal Cell Carcinoma","enrollment":20},{"nctId":"NCT03609944","phase":"NA","title":"SpHincterotomy for Acute Recurrent Pancreatitis","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2018-09-27","conditions":"Pancreatitis, Pancreas Divisum, Pancreatitis, Acute","enrollment":181},{"nctId":"NCT07299656","phase":"NA","title":"Outcome of Active Aspiration Versus Simple Compression to Remove Residual Gas From Abdominal Cavity in Reducing Pain After Laparoscopic Cholecystectomy","status":"NOT_YET_RECRUITING","sponsor":"King Edward Medical University","startDate":"2025-12-11","conditions":"Shoulder Pain, Abdominal Pain (AP)","enrollment":62},{"nctId":"NCT06764342","phase":"NA","title":"Adjunctive Effect of Photodynamic Therapy on Halitosis","status":"COMPLETED","sponsor":"Federal University of Minas Gerais","startDate":"2025-01-08","conditions":"Periodontitis, Halitosis","enrollment":40},{"nctId":"NCT00314405","phase":"NA","title":"Identification of Sentinel Lymph Nodes With Methylene Blue and Isotope","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2006-04","conditions":"Infiltrative Breast Cancer","enrollment":100},{"nctId":"NCT07150819","phase":"NA","title":"A Multidisciplinary Perioperative Pain Management","status":"WITHDRAWN","sponsor":"China-Japan Friendship Hospital","startDate":"2022-07-01","conditions":"Anorectal Surgery, Pain Management","enrollment":0},{"nctId":"NCT06335654","phase":"","title":"Real-time Artificial Intelligence-based Endocytoscopic Diagnosis of Colorectal Neoplasms","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2024-04-01","conditions":"Colorectal Neoplasms","enrollment":680},{"nctId":"NCT07254663","phase":"","title":"GEL & MEDication Dysphagia","status":"RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2025-09-15","conditions":"Neurological Diseases or Conditions, Healthy Participants","enrollment":500},{"nctId":"NCT07254260","phase":"","title":"Photodynamic Therapy and Post-Endodontic Pain in Undergraduate-Performed Treatments","status":"COMPLETED","sponsor":"Atlas University","startDate":"2025-01-01","conditions":"Pulpitis","enrollment":95},{"nctId":"NCT07242820","phase":"NA","title":"Reducing Neoplasia Recurrence After Non-thermal Endoscopic Resection of Large Colorectal Polyps","status":"NOT_YET_RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2025-12","conditions":"Colorectal Cancer, Polyp of Colon","enrollment":752},{"nctId":"NCT04354012","phase":"PHASE2","title":"Hidradenitis Suppurativa Wound Care","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-02-04","conditions":"Hidradenitis Suppurativa (HS)","enrollment":5},{"nctId":"NCT05897086","phase":"PHASE2, PHASE3","title":"Polyethylene-glycol Assisted Nerve Repair in Phalloplasty","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2023-08-01","conditions":"Gender Dysphoria","enrollment":30},{"nctId":"NCT07212842","phase":"PHASE2","title":"Methylene Blue-Enhanced Ultrafiltration Improves Outcomes After Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2021-04-12","conditions":"Cardiopulmonary Bypass Surgery, Aortic Valve Surgery, Mitral Valve Surgery","enrollment":124},{"nctId":"NCT07179003","phase":"PHASE2","title":"A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses","status":"NOT_YET_RECRUITING","sponsor":"University of Rochester","startDate":"2026-04","conditions":"Breast Abscess","enrollment":50},{"nctId":"NCT07169487","phase":"PHASE1","title":"Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"Cytokine Release Syndrome, ICANS","enrollment":18},{"nctId":"NCT07164807","phase":"PHASE4","title":"Efficacy of Methylene Blue Plus Ropivacaine for Post-Hemorrhoidectomy Pain.","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Putian University","startDate":"2025-08-30","conditions":"Mixed Hemorrhoids, Milligan-Morgan Hemorrhoidectomy, Methylene Blue","enrollment":177},{"nctId":"NCT07161856","phase":"NA","title":"Novel Balloon-Assisted vs Direct Technique in EUS-Guided Gastroenterostomy","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-09-01","conditions":"Gastric Outlet Obstruction","enrollment":272},{"nctId":"NCT07147452","phase":"","title":"Sentinel Lymph Node Detection in Gastric Cancer Using a Dual Tracer (Superparamagnetic Iron Oxide and Methylene Blue): A Prospective Study With Histological and OSNA Validation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital del SAS de Jerez","startDate":"2017-08-01","conditions":"Gastric Cancer (GC), Sentinel Lymph Node Biopsy (SLNB)","enrollment":44},{"nctId":"NCT06567691","phase":"NA","title":"Endoscopic Gastroenterostomy Versus Surgical Gastrojejunostomy","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2025-08-01","conditions":"Malignant Gastric Outlet Obstruction","enrollment":34},{"nctId":"NCT05664087","phase":"NA","title":"Effect of Photodynamic Therapy on Soft Tissue Healing After Tooth Extraction at Sites of Periodontal Infection","status":"COMPLETED","sponsor":"The Dental Hospital of Zhejiang University School of Medicine","startDate":"2023-02-14","conditions":"Periodontitis","enrollment":38},{"nctId":"NCT07129135","phase":"NA","title":"Effect of Methylene Blue Bladder Instillation on Urinary Tract Injuries During Cesarean Hysterectomy for Placenta Accreta Spectrum","status":"COMPLETED","sponsor":"Usama Ahmed Elsaeed Salem, MD","startDate":"2023-01-22","conditions":"Placenta Accreta Spectrum, Abnormal Placentation, Cesarean Hysterectomy","enrollment":60},{"nctId":"NCT04635605","phase":"PHASE2","title":"Methylene Blue Treatment of COVID-19","status":"COMPLETED","sponsor":"Fondazione Epatocentro Ticino","startDate":"2020-11-05","conditions":"SARS-CoV2","enrollment":29},{"nctId":"NCT06887036","phase":"PHASE2","title":"Methylene Blue Treatment of Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"Fondazione Epatocentro Ticino","startDate":"2025-09","conditions":"Chronic HBV Infection","enrollment":10},{"nctId":"NCT07114692","phase":"NA","title":"The Effect of Stromal Vascular Fraction Transplantation on the Regeneration of Expanded Skin","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2025-09-01","conditions":"Skin Regeneration","enrollment":20},{"nctId":"NCT01847612","phase":"PHASE3","title":"Use of Indocyanine Green Cholangiography and Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2013-07-08","conditions":"Liver Disease","enrollment":150},{"nctId":"NCT05774483","phase":"NA","title":"Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative","status":"RECRUITING","sponsor":"Tata Memorial Hospital","startDate":"2025-04-16","conditions":"Mouth Neoplasms, Oral Cancers, Oral Squamous Cell Carcinoma (OSCC)","enrollment":508},{"nctId":"NCT07067814","phase":"PHASE2, PHASE3","title":"Comparison Between Two Techniques During Thyroidectomy (Conventional Dissection Technique and Injection of Methylene Blue Dye Into Inferior Thyroid Artery Technique) Regarding Recurrent Laryngeal Nerve Identification and Preservation","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-06-01","conditions":"Time Taken for Identification of Single Recurrent Laryngeal Nerve, Intra-operative Blood Loss","enrollment":40},{"nctId":"NCT05830630","phase":"NA","title":"Perineural Methylene Blue Infusion in Lower Limb Amputation Surgery","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-05-01","conditions":"Perineural, Methylene Blue, Lower Limb Amputation","enrollment":72},{"nctId":"NCT05545787","phase":"NA","title":"Cold or Hot Snare Endoscopic Mucosal Resection for 10-19mm Non-pedunculated Colorectal Polyps","status":"RECRUITING","sponsor":"Qingwei Jiang","startDate":"2022-10-14","conditions":"Colorectal Polyp","enrollment":232},{"nctId":"NCT07012343","phase":"NA","title":"Exploring Different Dose-frequency Home Photodynamic Therapy Protocols Using a Novel Home-targeted LED Device for Onychomycosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chulalongkorn University","startDate":"2025-01-13","conditions":"Onychomycosis of Toenails, Onychomycosis of Fingernail","enrollment":50},{"nctId":"NCT06988774","phase":"NA","title":"Assessment of Tubal Occlusion During Minimally Invasive Myomectomy","status":"RECRUITING","sponsor":"Medstar Health Research Institute","startDate":"2025-06-02","conditions":"Fallopian Tube Patency Tests, Fibroid/Myoma (Uterus/Cervix), Myomectomy","enrollment":50},{"nctId":"NCT07040657","phase":"NA","title":"Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometrial Cancer Using Methylene Blue","status":"RECRUITING","sponsor":"Dokuz Eylul University","startDate":"2025-05-01","conditions":"Endometrial Neoplasms, Endometrial Cancer Stage I, Sentinel Lymph Node","enrollment":100},{"nctId":"NCT07038148","phase":"NA","title":"Exploring the Efficacy of Single-stage Stapled Conversion of Gastric Bypass to Sleeve Gastrectomy, More Leak?","status":"RECRUITING","sponsor":"Kasr El Aini Hospital","startDate":"2025-01-25","conditions":"the Focus of the Study is to Assees Efficacy of Stapled Revision of Gastric Bypass to Sleeve Gastrectomy","enrollment":11},{"nctId":"NCT07040020","phase":"NA","title":"This Randomized, Single-center Trial Aims to Evaluate the Advantages of Underwater ESD (U-ESD) in Comparison to the Conventional ESD (C-ESD).","status":"RECRUITING","sponsor":"Istituto Clinico Humanitas","startDate":"2025-03-31","conditions":"Precancerous Lesions","enrollment":122},{"nctId":"NCT06731881","phase":"NA","title":"Assessing the Efficacy of Photodynamic Therapy for Preventing Surgical Site Infections","status":"RECRUITING","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2025-06-04","conditions":"Surgery, Nasal Disease, Light; Therapy, Complications","enrollment":80},{"nctId":"NCT07012707","phase":"","title":"Rationale and Trial Design of PFB-03 Study: Diagnostic Performance and Clinical Application of 18F-FAPI-PET/CT for Detecting Axillary Lymph Node Metastasis in Breast Cancer Patients After Neoadjuvant Therapy","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-06-01","conditions":"Breast Cancer","enrollment":172},{"nctId":"NCT02478281","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2012-10","conditions":"Methemoglobinemia, Congenital Methemoglobinemia","enrollment":12},{"nctId":"NCT04171531","phase":"PHASE3","title":"Sling vs Botox for Mixed Incontinence","status":"COMPLETED","sponsor":"NICHD Pelvic Floor Disorders Network","startDate":"2020-06-08","conditions":"Urinary Incontinence, Stress, Urinary Incontinence, Urge","enrollment":150},{"nctId":"NCT06761287","phase":"NA","title":"Optimizing Patient Selection for Surgery Using Pathologic Analysis Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2025-03-28","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":20},{"nctId":"NCT04791735","phase":"NA","title":"Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-21","conditions":"Hepatocellular Carcinoma","enrollment":252},{"nctId":"NCT05942118","phase":"","title":"Comparison Between ROLL Versus Magnetic Seed for Preoperative Localization of Non-palpable Breast Lesion by Randomized Clinical Study.","status":"RECRUITING","sponsor":"Istituti Clinici Scientifici Maugeri SpA","startDate":"2023-05-31","conditions":"Breast Cancer","enrollment":262},{"nctId":"NCT06324097","phase":"","title":"Diagnostic Value of Endocytoscopy for Colorectal Lesions","status":"COMPLETED","sponsor":"Hong Xu","startDate":"2024-04-01","conditions":"Colorectal Neoplasms","enrollment":463},{"nctId":"NCT04529265","phase":"NA","title":"Methylene Blue and Postoperative Neurocognitive Disorders","status":"COMPLETED","sponsor":"Fudan University","startDate":"2021-05-01","conditions":"Postoperative Delirium","enrollment":314},{"nctId":"NCT04201717","phase":"NA","title":"Intracorporeal Anastomosis Versus Extracorporeal Anastomosis for Left Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jilin University","startDate":"2021-01-27","conditions":"Colon Cancer","enrollment":350},{"nctId":"NCT06789965","phase":"NA","title":"Comparison of Two Surgical Techniques for Treatment of Type III Obesity (BMI 40-50 kg/m2): Single Anastomosis Duodenoileal Bypass With Sleeve Gastrectomy and Roux-en-Y Gastric Bypass.","status":"RECRUITING","sponsor":"Hospital Clinic of Barcelona","startDate":"2025-02-01","conditions":"Obesity","enrollment":450},{"nctId":"NCT05878405","phase":"PHASE3","title":"Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2023-06-06","conditions":"Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Stomatitis","enrollment":49},{"nctId":"NCT04036942","phase":"NA","title":"Antireflux Ablation Therapy (ARAT) Vs Antireflux Mucosectomy (ARMS) In The Management Of Gastroesophageal Reflux Disease","status":"WITHDRAWN","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2019-07-15","conditions":"Gastroesophageal Reflux Disease","enrollment":0},{"nctId":"NCT06931678","phase":"NA","title":"Photodynamic Therapy in Root Canal Treatment of T2DM Patients: Microbiome Analysis Via Next-Gen Sequencing","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2024-10-21","conditions":"Type 2 Diabetes Mellitus (T2DM), Necrotic Pulp, Apical Periodontitis","enrollment":20},{"nctId":"NCT05898035","phase":"NA","title":"Postoperative Symptoms Following Endodontic Microsurgery","status":"RECRUITING","sponsor":"King Abdullah University Hospital","startDate":"2022-02-01","conditions":"Pain Postoperative, Swelling Lips & Face","enrollment":40},{"nctId":"NCT05092165","phase":"PHASE2","title":"Methylene Blue for the Prevention of Hypotension During Hemodialysis","status":"RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2021-10-21","conditions":"Acute Kidney Injury, Shock","enrollment":260},{"nctId":"NCT05713955","phase":"PHASE2","title":"OBSiDiAN in a Stapled Circular Esophagogastric Anastomosis After Ivor Lewis Esophagectomy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2025-04-01","conditions":"Anastomotic Leak Esophagus","enrollment":90},{"nctId":"NCT06870903","phase":"NA","title":"Comparison of Transvaginal Paracervical and Transperitoneal Approaches in Lymphadenectomy During v-NOTES Surgery for Patients Diagnosed With Endometrial Cancer","status":"RECRUITING","sponsor":"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital","startDate":"2025-03-15","conditions":"Endometrial Cancer, Lymphadenectomy, Sentinel Lymph Node Biopsy","enrollment":52},{"nctId":"NCT04276532","phase":"NA","title":"Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiaojun Chen","startDate":"2020-02-13","conditions":"Middle-high Risk Endometrial Cancer, Sentinel Lymph Node Sampling, Prognosis","enrollment":780},{"nctId":"NCT06834087","phase":"NA","title":"Laser Treatment with Methylene Blue Vs. Nanoparticle-Assisted Photodynamic Therapy for Gingival Pigmentation: a Randomized Clinical Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Roaa Hadi Hussein Jasem","startDate":"2025-03-15","conditions":"Physiological Gingival Pigmentation","enrollment":45},{"nctId":"NCT06747195","phase":"","title":"The Impact of Methylene Blue on the Quality of Recovery in Patients Undergoing Hemorrhoidectomy","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-01-01","conditions":"Hemorrhoidectomy, Postoperative Analgesia","enrollment":290},{"nctId":"NCT06641375","phase":"NA","title":"Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: A Single Center, Randomized, Sham, Controlled Trial (The AREA Study)","status":"RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2024-02-10","conditions":"GERD","enrollment":18},{"nctId":"NCT06815705","phase":"NA","title":"Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-03-20","conditions":"Head and Neck Squamous Cell Carcinoma, Lymphedema, Secondary, Neck Lymph Dissection","enrollment":23},{"nctId":"NCT06801938","phase":"NA","title":"Evaluation of Perioperative Cystoscopy and Methylene Blue Test in Detecting Complications in TVT and TOT Procedures","status":"RECRUITING","sponsor":"Gaziosmanpasa Research and Education Hospital","startDate":"2025-01-01","conditions":"Incontinence Stress","enrollment":58},{"nctId":"NCT06284941","phase":"NA","title":"A Study of Ropivacaine Complex Methylene Blue Fascia Iliaca Compartment Block on Analgesia in Patients Undergoing Hip Arthroplasty","status":"COMPLETED","sponsor":"Wang wanxia","startDate":"2023-06-20","conditions":"Femoral Neck Disease","enrollment":90},{"nctId":"NCT06785233","phase":"NA","title":"Endoscopic Treatment of Overweight and Mild Obesity with ORBERA365","status":"RECRUITING","sponsor":"Kaiser Clinic and Hospital","startDate":"2025-01","conditions":"Obesity, Obesity, Morbid","enrollment":30},{"nctId":"NCT04362774","phase":"","title":"ORBERA365 Post-Marketing Clinical Follow-up Study","status":"TERMINATED","sponsor":"Apollo Endosurgery, Inc.","startDate":"2021-02-23","conditions":"Obesity, Overweight","enrollment":25},{"nctId":"NCT06481410","phase":"NA","title":"Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-22","conditions":"Septic Shock, Methylene Blue, Sepsis","enrollment":488},{"nctId":"NCT06073704","phase":"NA","title":"Effects of Adjunct Antimicrobial Photodynamic Therapy in Periodontal Treatment of Patients with Obesity","status":"RECRUITING","sponsor":"University of Sao Paulo","startDate":"2023-10-09","conditions":"Periodontitis, Obesity","enrollment":24},{"nctId":"NCT05603442","phase":"PHASE3","title":"Thoracic Intervertebral Foramen Block","status":"COMPLETED","sponsor":"San Salvatore Hospital of L'Aquila","startDate":"2022-06-07","conditions":"Anesthesia; Functional, Anesthesia, Local, Spinal Cord","enrollment":5},{"nctId":"NCT04842968","phase":"NA","title":"Ex Vivo Intraarterial Methylene Blue Injection Improve Nodal Staging Accuracy in Colorectal Cancer","status":"COMPLETED","sponsor":"St. Borbala Hospital","startDate":"2021-04-15","conditions":"Lymph Node Metastases, Colorectal Cancer","enrollment":200},{"nctId":"NCT06469294","phase":"NA","title":"Evaluation of Chlorhexidine Gel Associated with Photodynamic Therapy in the Treatment of Chronic Periodontitis in Type 2 Diabetics","status":"COMPLETED","sponsor":"Universidade Federal Fluminense","startDate":"2024-05-30","conditions":"Diabetes Mellitus, Type 2, Periodontitis, Adult, Periodontitis","enrollment":20},{"nctId":"NCT04292496","phase":"NA","title":"Anastomotic Leak Testing in Gastrectomy","status":"COMPLETED","sponsor":"Nanchong Central Hospital","startDate":"2018-09-01","conditions":"Anastomotic Leak, Gastric Cancer, Surgery","enrollment":148},{"nctId":"NCT06015165","phase":"NA","title":"Outcomes for Anesthesiologist-Led Care of Analgesic Protocol in Anorectal Surgery","status":"RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2024-09-10","conditions":"Postoperative Pain","enrollment":216},{"nctId":"NCT05950737","phase":"NA","title":"Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience","status":"COMPLETED","sponsor":"Tata Memorial Hospital","startDate":"2021-06-01","conditions":"Oral Cavity Squamous Cell Carcinoma","enrollment":115},{"nctId":"NCT06660680","phase":"PHASE3","title":"The Effect of Methylene Blue Infiltrating Injection on Anal Pain After Milligan-Morgan Surgery: a Randomized Controlled Clinical Study","status":"ENROLLING_BY_INVITATION","sponsor":"The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine","startDate":"2024-10-25","conditions":"Mixed Hemorrhoids","enrollment":60},{"nctId":"NCT05117879","phase":"NA","title":"R0 Resection Rate Between CSP, cEMR and hEMR for 1-2 cm Colorectal SSLs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2020-12-10","conditions":"Residual Disease","enrollment":120}],"_emaApprovals":[{"date":"","name":"methylthioninium benzalkonium chloride hydrate","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[{"role":"Manufacturer","site":"Meitheal Pharmaceuticals Inc.","location":"","operator":"Meitheal Pharmaceuticals Inc."}],"molecularData":{"oral":false,"chemblId":"CHEMBL550495","moleculeType":"Small molecule","molecularWeight":"373.91"},"administration":{"icon":"💊","route":"Oral","frequency":"4 times per day","formulation":"benzoic acid 9 MG / hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG Oral Tablet [Hyophen]; hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet [Phosphasal]; hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet [Utira]","formulations":[{"form":"CAPSULE","route":"ORAL","tradeName":"URO-SP"},{"form":"CAPSULE","route":"ORAL","tradeName":"URIBEL"},{"form":"CAPSULE","route":"ORAL","tradeName":"URIMAR-T CAPS"},{"form":"CAPSULE","route":"ORAL","tradeName":"UrNeva"},{"form":"CAPSULE","route":"ORAL","tradeName":"Uro-MP"},{"form":"CAPSULE","route":"ORAL","tradeName":"UroAv-B"},{"form":"CAPSULE","route":"ORAL","tradeName":"Ustell"},{"form":"INJECTION","route":"INTRAVENOUS","tradeName":"PROVAYBLUE"},{"form":"INJECTION","route":"INTRAVENOUS","tradeName":"Methylene Blue"},{"form":"TABLET","route":"ORAL","tradeName":"URELLE"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146895","MMSL":"1036","NDDF":"001094","UNII":"T42P99266K","VUID":"4018579","CHEBI":"CHEBI:6872","VANDF":"4018579","RXNORM":"6878","UMLSCUI":"C0025746","chemblId":"CHEMBL550495","ChEMBL_ID":"CHEMBL550495","KEGG_DRUG":"D02312","DRUGBANK_ID":"DB09241","PDB_CHEM_ID":" MBT","PUBCHEM_CID":"6099","SNOMEDCT_US":"354064008","SECONDARY_CAS_RN":"7220-79-3","MESH_DESCRIPTOR_UI":"D008751"},"formularyStatus":[],"_approvalHistory":[{"date":"20250730","type":"ORIG","sponsor":"XIROMED","applicationNumber":"ANDA219363"},{"date":"20250123","type":"ORIG","sponsor":"MEITHEAL","applicationNumber":"ANDA217380"},{"date":"20231205","type":"ORIG","sponsor":"ZYDUS LIFESCIENCES","applicationNumber":"ANDA215636"},{"date":"20250304","type":"SUPPL","sponsor":"ZYDUS LIFESCIENCES","applicationNumber":"ANDA215636"},{"date":"20260202","type":"SUPPL","sponsor":"ZYDUS LIFESCIENCES","applicationNumber":"ANDA215636"},{"date":"20241122","type":"ORIG","sponsor":"STERISCIENCE","applicationNumber":"ANDA216955"},{"date":"20241217","type":"ORIG","sponsor":"HIKMA","applicationNumber":"ANDA216959"}],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"2016-present","_source":"FDA label","companyName":"PROVEPHARM SAS","relationship":"Originator"}],"pharmacokinetics":{"source":"FDA label","halfLife":"24 hours"},"publicationCount":26980,"therapeuticAreas":["Oncology"],"trialPhaseCounts":{"":6,"NA":24,"PHASE1":2,"PHASE2":4,"PHASE3":7,"PHASE4":2,"EARLY_PHASE1":1,"PHASE1, PHASE2":1,"PHASE2, PHASE3":3},"atcClassification":{"source":"RxNav","atcCode":"V03AB17","atcName":"Methylene Blue"},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jun 1","pmid":"41943352","title":"Compressible lignin-enhanced holocellulose aerogel for adsorption applications.","journal":"Carbohydrate polymers"},{"date":"2026 Jun 1","pmid":"41943332","title":"Acid-treated sodium alginate-based composite gel microspheres toward methylene blue removal: Fabrication and mechanistic insights.","journal":"Carbohydrate polymers"},{"date":"2026 Apr 6","pmid":"41940867","title":"Serratus Anterior Plane Block with Methylene Blue and Ropivacaine for analgesia in Prosthetic Breast Augmentation: A Randomized Controlled Trial.","journal":"Plastic and reconstructive surgery"},{"date":"2026 Mar","pmid":"41940357","title":"Approaching spectrophotometric analysis in apical sealing ability performed with three different sealers mixed with chitosan nanoparticles: An in vitro study.","journal":"Journal of conservative dentistry and endodontics"},{"date":"2026 Mar 31","pmid":"41939367","title":"Lotus-Shaped CuO/ZnO Nanocomposites with Tunable Band Gap for UVA-Induced Photocatalytic Degradation of Organic Dyes.","journal":"ACS omega"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"genericManufacturers":["XIROMED","HIKMA","MEITHEAL","CHENGDU SHUODE","NEXUS","PROVEPHARM SAS","STERISCIENCE","ZYDUS LIFESCIENCES"],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2016","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":7,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:03:32.401887+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}